Vertex price target lowered to $41 from $56 at BMO Capital
BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the ...
AFP1d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...
MarketWatch13d
GE Aerospace looks to ‘compound’ investor returns. Stock soars to 18-year high.
Shares of GE Aerospace soared to levels not seen in nearly two decades on Thursday, after the maker of engines used by airlines and the military provided an upbeat earnings outlook for 2025 and ...
Business Insider18d
Vertex Pharmaceuticals (VRTX) Sees Strong 2025 Revenue Growth
Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst expectations, driven by strong demand for its cystic ...
AZOM22d
Bruker Launches the VERTEX NEO Platform
Bruker Corporation announced the launch of the VERTEX NEO Platform with its first product, the VERTEX NEO R. This release marks a continuation of providing high-end Fourier-Transform Infrared (FTIR) ...
The Motley Fool25d
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...
Flightglobal26d
Why down-to-earth approach has Vertical Aerospace looking up
That aircraft is the second prototype of the VX4, an electric vertical take-off and landing (eVTOL) vehicle developed by Bristol, UK-headquartered Vertical Aerospace. A four-passenger, crewed ...
The Motley Fool27d
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...
Yahoo Finance27d
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating ...
ETF Daily News27d
Vertex Pharmaceuticals’ (VRTX) “Hold” Rating Reiterated at Needham & Company LLC
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) ‘s stock had its “hold” rating reaffirmed by Needham & Company LLC in a report released on Friday,Benzinga reports.A number of other ...
The Boston Globe28d
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...